Table 2.
Treatment
| MPM (n=11 539) | MPeM (n=629) | Total (N=12 168) | |
| All, n (%)* | |||
| Chemotherapy | 3273 (28.4) | 142 (22.6) | 3415 (28.1) |
| Surgery | 343 (3.0) | 65 (10.3) | 408 (3.4) |
| Radiotherapy | 1072 (9.3) | 4 (0.6) | 1076 (8.8) |
| Immunotherapy | 52 (0.5) | 3 (0.5) | 55 (0.5) |
| Targeted therapy | 72 (0.6) | 2 (0.3) | 74 (0.6) |
| Best supportive care | 7132 (61.8) | 423 (67.2) | 7555 (62.1) |
| Unknown | 144 (1.2) | 7 (1.1) | 151 (1.2) |
| Multimodal treatment, n (%) | |||
| Chemotherapy and surgery | 92 (0.8) | 10 (1.6) | 102 (0.8) |
| Chemotherapy and radiotherapy | 252 (2.2) | 1 (0.2) | 253 (2.1) |
| Chemotherapy and targeted therapy | 44 (0.4) | 1 (0.1) | 45 (0.4) |
| Chemotherapy and immunotherapy | 11 (0.1) | – | 11 (0.1) |
| Surgery and radiotherapy | 47 (0.4) | 2 (0.3) | 49 (0.4) |
| Surgery and chemotherapy and radiotherapy | 40 (0.3) | – | 40 (0.3) |
| Other | 9 (0.1) | 3 (0.5) | 12 (0.1) |
| Total | 495 (4.3) | 17 (2.7) | 512 (4.2) |
| Reason for no treatment (ie, BSC), n (%)† | |||
| Comorbidity | 18 (2.1) | 3 (5.9) | 21 (2.3) |
| Performance status | 214 (25.3) | 16 (31.4) | 230 (25.6) |
| Age | 32 (3.8) | 1 (2) | 33 (3.7) |
| Patient preference | 363 (42.9) | 14 (27.5) | 377 (42) |
| Disease too extensive | 55 (6.5) | 8 (15.7) | 63 (7) |
| Deceased before start of treatment | 30 (3.5) | 0 (0) | 30 (3.3) |
| Other/unknown | 135 (15.9) | 9 (17.6) | 144 (16) |
*Total percentage >100% due to 4.2% of patients receiving multimodal treatment.
†Registered for 898 patients (847 pleural, 51 peritoneal); percentages based on registered cases.
BSC, best supportive care; MPeM, malignant peritoneal mesothelioma; MPM, malignant pleural mesothelioma.